Navigation Links
New drug for breast cancer prevention produced by Arimidex

The number of breast cancer cases has reached about 1.2 million worldwide and Statistics show that the incidence of breast cancer is rapidly increasing in urban India and has overtaken cancer of the cervix as the number one cancer // in our major metros according to a study conducted on women and cancer in India. Oil foods, obesity, smoking, drinking, late marriage and delayed motherhood are some factors that can lead to a high risk of breast cancer.

The new drug that is being manufactured by the pharmaceutical company Arimidex is said to prevent occurrence of recurrence of breast cancer after surgery. Arimidex claims that its new drug is 26% more effective than the current drugs in preventing breast cancer recurrence. The Breast Cancer Care Scotland his very happy and it expressed that it will be helpful for women in Scotland with breast cancer. The new drug, which has been approved by Scottish Medicines Consortium, is yet to get approved for general use in England. The new drug will be very helpful for all post-menopausal women with early breast cancer as the drug has to be taken after surgery and it significantly reduces the occurrence of recurrence breast cancer.

Leading breast cancer surgeon Dr Chris Wilson, of Glasgow's Western Infirmary, said:
'"/>




Page: 1

Related medicine news :

1. Ductal lavage may detect early breast cancer
2. Exclusive breast-feeding advised for six months in infants recommends World Health Organization
3. Micro-camera provides new breast imaging technique
4. Support therapy helps breast cancer patients
5. Variation in breast cancer
6. Appropriate treatment for breast cancer
7. Combination therapy to treat breast cancer
8. Hope for breast cancer patients
9. Pregnancy weight linked to breast cancer
10. New breast cancer genes discovered
11. New breast cancer drug appears encouraging
Post Your Comments:
Breaking Medicine Technology:Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Zyomyx Point of Care CD4 Test Selected by CD4 Initiative to Help Treat HIV AIDS Patients in Developing Countries 6315 1Zyomyx Point of Care CD4 Test Selected by CD4 Initiative to Help Treat HIV AIDS Patients in Developing Countries 6315 2Zyomyx Point of Care CD4 Test Selected by CD4 Initiative to Help Treat HIV AIDS Patients in Developing Countries 6315 3Mercy Health Plans Receives Five Star Excellent Rating 61479 1Mercy Health Plans Receives Five Star Excellent Rating 61479 2Vibrations key to efficiency of green fluorescent protein 14861 1Vibrations key to efficiency of green fluorescent protein 14861 2Vibrations key to efficiency of green fluorescent protein 14861 3Vibrations key to efficiency of green fluorescent protein 14861 4